Clinical Trials on Advanced Lymphoma in France

Total 1710 results

European Organisation for Research and Treatment...
Acute Leukemia French Association

Completed

Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Lymphoblastic Leukemia

Lymphoma | Leukemia

France, Belgium, Netherlands, Italy, Czech Republic, Portugal, Croatia, Turkey, Germany, Slovakia
Morphotek
National Cancer Institute (NCI); Children's Oncology Group

Completed

MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma

Unspecified Childhood Solid Tumor, Protocol Specific | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma and other conditions

United States
Weprom
Takeda; SIVAN Innovation

Terminated

Relevance of a Web-mediated Follow up in Patients Having a Lymphoma With a High Risk of Relapse in Complete or Partial Response

Lymphoma, Large B-Cell, Diffuse | Lymphoma, T-Cell | Lymphoma, Hodgkin

France
Gustave Roussy, Cancer Campus, Grand Paris
Children's Oncology Group

Active, not recruiting

Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation

Primary Mediastinal Large B Cell Lymphoma

France, Belgium, United Kingdom, Netherlands, Canada, Hungary, Italy, Poland, Spain
The Lymphoma Academic Research Organisation
Pfizer; Takeda; Hôpital Necker-Enfants Malades; Fondation ARC

Completed

Prospective Study of the Prognostic Value of New Markers in Adults With ALK-positive Large Anaplastic Lymphoma

Anaplastic Large Cell Lymphoma, ALK-Positive

France
Group for Research in Adult Acute Lymphoblastic...
Amgen

Unknown

Efficacy and Toxicity of Blinatumomab in the French ATU for Adult BCP-ALL R/R, or With MRD+ (FRENCH-CYTO) (FRENCH-CYTO)

Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia With Failed Remission

France
BeiGene

Recruiting

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Follicular Lymphoma | Waldenström Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma | B-cell Malignancy

United States, Spain, Italy, Australia, France, Korea, Republic of, United Kingdom, Canada, Brazil, Georgia, Sweden, Germany, Moldova, Republic of
Genentech, Inc.

Completed

A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma

Lymphoma, Non Hodgkin

United States, France
Kite, A Gilead Company

Completed

Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma (ZUMA-12)

B-cell Lymphoma

United States, Australia, France
Centre Francois Baclesse
Ligue contre le cancer, France

Recruiting

Optimize the Support of Patients in Pelvic Onco-gynecology Through Adapted Support Care in the Post-cancer Period. AFTERGYN Pilot Phase (AFTERGYN)

Long Term Cancer Side Effects | Supportive Care in Cancer | Cancer Survivorship Care Plan | Advanced Nurse Practitioner | Pelvic Gynecological Cancer

France
Gilead Sciences

Terminated

Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)

Non-Hodgkin Lymphoma

United States, France
Centre Leon Berard
NETRIS Pharma

Recruiting

NP137 Clinical and Biological Activities Assessment in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Anti PD-1/PD-L1 Immunotherapies (IMMUNONET)

Advanced Solid Tumors | Metastatic Solid Tumors

France
The Lymphoma Academic Research Organisation

Completed

Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular Lymphoma (iLOC)

Intraocular Lymphoma | Primary Central Nervous Lymphoma

France
Celgene

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma

Lymphoma, Non-Hodgkin

France, Spain
Centre Henri Becquerel
U918 ( Inserm unit)

Completed

Assessment of the Minimal Residual Disease in DLBCL From Cell-free Circulating DNA by NGS (LymphoSeq)

Non Hodgkin Lymphoma

France
Bayer

Completed

Copanlisib Pharmacodynamic Study

Non Hodgkin Lymphoma

Belgium, France, United Kingdom
University of Alberta
Alberta Health services

Active, not recruiting

A Feasibility Study of a Virtual Rehabilitation and Physical Activity Program for People With Advanced Cancer (ACTIVE-North)

Advanced Cancer

Canada
Assistance Publique - Hôpitaux de Paris

Recruiting

Multicenter Trial Treatment of Philadelphia Chromosome Negative B-cell Acute Lymphoblastic Leukemia of Young Adults (GRAALL-2014/B)

Philadelphia Chromosome Negative Adult B-cell Acute Lymphoblastic Leukemia

France
The Lymphoma Academic Research Organisation
Centre Henri Becquerel

Completed

Revlimid Dose 25 mg in Association With (R-CHOP) in the Treatment Follicular Lymphoma (R2-CHOP2)

Follicular Lymphoma

France
Eli Lilly and Company

Completed

Chemotherapy for Participants With Lymphoma

Lymphoma, Large Cell, Diffuse

France, Germany, Russian Federation
Pfizer

Completed

A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer (PROFILE 1001)

Systemic Anaplastic Large-Cell Lymphoma | Non-Small Cell Lung Cancer ALK-positive | Non-Small Cell Lung Cancer c-Met Dependent | Non-Small Cell Lung Cancer ROS Marker Positive | Advanced Malignancies Except Leukemia

United States, Korea, Republic of, Australia, Japan
Sanofi

Terminated

Rasburicase for the Treatment/Prevention of Hyperuricemia in Adult Patients With Relapsing Aggressive Non Hodgkin's Lymphoma (GRAAL2)

Hyperuricemia

Germany, Belgium, Italy, France
PIQUR Therapeutics AG

Withdrawn

PQR309 in Phase 2 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma

Primary Central Nervous System Lymphoma

France
Lymphoma Study Association

Unknown

Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma

Lymphoma

United Kingdom, France
Incyte Corporation

Active, not recruiting

A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) (topMIND)

Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma

United States, Spain, France, Italy, Belgium, Germany, Austria
Shanghai Henlius Biotech

Withdrawn

A Phase 1 Study of the CD73 Inhibitor(HLX23) Alone in Participants With Solid Tumor

Advanced Solid Tumor

United States
Loxo Oncology, Inc.
Eli Lilly and Company

Active, not recruiting

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

B-cell Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, Korea, Republic of, Australia, Japan, United Kingdom, Italy, Poland, France, Switzerland, Sweden
Hoffmann-La Roche

Completed

A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

Lymphoma

United States, France, Germany, Italy, United Kingdom
Innate Pharma

Recruiting

Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma

Non Hodgkin Lymphoma

France, United States, Australia
Novartis Pharmaceuticals

Completed

Safety and Efficacy of BKM120 in Relapsed and Refractory NHL

Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma

United States, Belgium, Germany, France, Italy, Korea, Republic of, Spain, Turkey
MedImmune LLC

Completed

IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.

Advanced Solid Tumors

United States, France, Spain, Switzerland
Xencor, Inc.
ICON Clinical Research

Active, not recruiting

Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies

Chronic Lymphocytic Leukemia | B-cell Non-Hodgkins Lymphoma

United States, France, Korea, Republic of, United Kingdom
Merck Sharp & Dohme LLC

Recruiting

A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

Follicular Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Richter Transformation Lymphoma

Poland, United States, Canada, China, Estonia, Israel, Italy, Korea, Republic of, Spain, Sweden, Turkey, Czechia, Germany, Chile, Brazil, Portugal, Ireland, Singapore, United Kingdom, Japan, Peru
The Lymphoma Academic Research Organisation

Active, not recruiting

Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation

B-cell Lymphoma Recurrent | B-Cell Lymphoma Refractory

France, Belgium
Celgene

Terminated

Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma

Lymphoma, Large B-Cell, Diffuse

United States, France, Canada, Italy
Institut Curie

Active, not recruiting

The Integrated Support and Palliative in Cancer Day-care Hospital for Patients With Advanced Cancers: Impact on Quality of Life, Care Pathways and Support for Caregivers (HDJ-SPI)

Cancer, Advanced

France
National Cancer Institute (NCI)

Active, not recruiting

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

T Acute Lymphoblastic Leukemia | T Lymphoblastic Lymphoma

United States, Canada, Australia, New Zealand, Switzerland
Regeneron Pharmaceuticals

Recruiting

A Trial to Learn if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Participants With Follicular Lymphoma and Marginal Zone Lymphoma (OLYMPIA-5)

Relapsed/Refractory Follicular Lymphoma | Marginal Zone Lymphoma (MZL)

Italy, Korea, Republic of, Australia, France, Spain, Malaysia, Taiwan, Poland, United States, United Kingdom, Turkey, Belgium, Thailand, Czechia
Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 in Patients With HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer

Advanced Solid Tumors | Advanced or Metastatic Gastric Cancer | Advanced or Metastatic Gastroesophageal Junction Cancer

United States
University Hospital, Caen

Recruiting

Clozapine and Haematologic Malignancies: Observational and Retrospective Study Using the WHO Pharmacovigilance Database (CLOZARIX)

Lymphoma | Leukemia

France
Hospices Civils de Lyon
The Lymphoma Academic Research Organisation

Recruiting

REal World Data in LYmphoma and Survival in Adults (REALYSA)

Mantle Cell Lymphoma (MCL) | Follicular Lymphoma (FL) | Diffuse Large B Lymphoma (DLBCL) | Marginal Zone Lymphoma (MZL) | T-cell Lymphoma (T-NHL) | Hodgkin's Lymphoma (HL) | Burkitt Lymphoma (BL))

France
National Cancer Institute (NCI)
Southwest Oncology Group

Completed

506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Lymphoma | Leukemia

United States
Amunix, a Sanofi Company
Merck Sharp & Dohme LLC

Recruiting

To Access the Safety and Effects of Intravenous Administration of AMX-818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers

Locally Advanced or Metastatic HER2-Expressing Cancers

Australia, Spain, France, Portugal
Innate Pharma
AstraZeneca

Terminated

IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors (STELLAR-001)

Advanced Solid Tumors

United States, France
Step Pharma, SAS

Recruiting

A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas

Lymphoma, B-Cell | Lymphoma, T-Cell

United States, France, United Kingdom
Gustave Roussy, Cancer Campus, Grand Paris

Recruiting

Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2) (NIVO-ALCL)

Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma

France, Denmark, Netherlands
Amgen

Completed

Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease

Type II Refractory Celiac Disease (RCD-II) | In-situ Small Bowel T-cell Lymphoma

Spain, United States, Finland, France, Netherlands
Sanofi

Completed

Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma

Norway, Austria, France
BeiGene

Completed

Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms

Cutaneous T-cell Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Adult Nasal Type Extranodal NK/T-cell Lymphoma | Anaplastic Large Cell Lymphoma, ALK-Positive | Extranodal NK/T-cell Lymphoma, Nasal Type | Peripheral T Cell Lymphoma | Extranodal NK/T-cell Lymphoma | Peripheral... and other conditions

China, Taiwan, Germany, France, Canada, Italy
University Hospital, Montpellier
University Hospital, Bordeaux; University Hospital, Toulouse

Completed

South Of France Cardiac Assist Registry (SOFCAR)

Chronic or Acute Advanced Heart Failure

France

Clinical Trials on Advanced Lymphoma in France

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Finland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations